The Maharashtra Food and Drug Administration has withdrawn its order cancelling the drug sale licence of Cipla Pharma and Life Sciences Ltd’s carrying and forwarding facility at Wadki in Pune.
The decision followed strong observations from the Bombay High Court, which questioned the procedure adopted by the regulator while cancelling the licence. The court observed that the FDA had acted in a high handed manner and appeared to have proceeded against the principles of natural justice.
Following the court’s intervention, the Maharashtra FDA informed the bench that it would withdraw the cancellation order immediately. The regulator also agreed to issue a fresh show cause notice to Cipla and conduct the proceedings again before passing a reasoned order.
The matter concerns Cipla Pharma and Life Sciences Ltd’s carrying and forwarding facility at Wadki in Pune. The FDA had cancelled the drug sale licences with effect from August 27 following inspections that identified alleged regulatory irregularities.
The original action was connected to Reactin Plus tablets, which are classified as a Schedule H prescription medicine. According to reports, the FDA raised concerns over the packaging, storage and recall procedures associated with the product.
The regulator had reportedly objected to wording and promotional material appearing on the packaging of Reactin Plus. Officials said the packaging contained references that were considered inconsistent with provisions under the Drugs and Cosmetics Act and Rules.
The FDA also cited other alleged compliance issues during its inspections. These included discrepancies between physical and digital stock records, shortcomings in maintaining purchase and sales documentation and concerns regarding compliance with recall instructions.
The regulator had also seized stock of Reactin Plus valued at approximately Rs 11.19 lakh and directed that the affected stock be withdrawn from the market, according to reports.
Cipla challenged the cancellation before the Bombay High Court. The company maintained that the regulatory action did not raise concerns regarding the safety, quality or efficacy of its products and did not indicate a patient safety issue.
During the court proceedings, Cipla’s lawyers questioned the manner in which the hearing process had been conducted.
According to the company’s submissions, the FDA had asked Cipla to appear for a hearing on August 26. The date was reportedly a state declared public holiday, and Cipla requested an adjournment because a company representative was not available.
The FDA nevertheless proceeded with the cancellation order, according to the submissions made before the High Court. This became a key issue during the hearing because the court examined whether the company had been given a proper opportunity to present its case.
The Bombay High Court questioned the fairness of the process and emphasised the importance of following the principles of natural justice when taking regulatory action against a company.
Natural justice generally includes basic procedural safeguards, including giving an affected party a meaningful opportunity to respond before an adverse administrative decision is taken.
The court’s observations prompted the FDA to reconsider its immediate approach. Rather than defending the cancellation order in its existing form, the regulator agreed to withdraw it and begin the process again.
The fresh proceedings will involve a new show cause notice to Cipla. The company will have an opportunity to respond to the allegations, after which the regulator is expected to examine the matter and issue a reasoned decision.
The withdrawal of the order does not mean that the underlying regulatory concerns have been permanently dismissed. The FDA can continue examining the alleged violations through the fresh proceedings.
This distinction is important because the High Court’s criticism was primarily related to the procedure followed by the regulator. The court did not, at this stage, determine the final merits of all the allegations concerning the medicines or the Pune facility.
The FDA’s decision to restart the process therefore leaves the substantive regulatory issues open for consideration.
For Cipla, the development provides temporary relief from the immediate effect of the licence cancellation. The company can now participate in the fresh proceedings and present its position before the regulator.
For the Maharashtra FDA, the case highlights the importance of following due process while taking enforcement action against pharmaceutical companies.
Drug regulators play an important role in ensuring that medicines are manufactured, stored, distributed and sold in accordance with legal and safety requirements. At the same time, regulatory decisions can have significant commercial and operational consequences for pharmaceutical companies.
The case therefore illustrates the need to balance strict enforcement with procedural fairness.
The original FDA action came after inspections of Cipla’s Pune warehouse. The regulator had stated that strict compliance with legal requirements was essential, particularly for Schedule H prescription medicines.
Schedule H medicines are prescription drugs that are subject to specific regulatory requirements concerning their sale and distribution.
The FDA’s concerns over Reactin Plus reportedly included packaging and promotional wording, as well as issues involving storage and stock records. These matters will now be considered again as part of the fresh proceedings.
The court’s intervention also underscores the role of judicial review in administrative decisions. When companies challenge regulatory orders, courts can examine whether authorities have acted within the law and followed appropriate procedures.
In this case, the Bombay High Court questioned the process used by the FDA and prompted the regulator to withdraw the existing cancellation order.
The FDA is expected to issue a fresh show cause notice to Cipla. The company will then have the opportunity to respond to the allegations before a new decision is taken.
The eventual outcome could depend on the findings of the fresh proceedings and the evidence presented by both sides.
The episode also highlights the importance of maintaining accurate records within pharmaceutical supply chains. Proper documentation of stock, purchases, sales, storage and recalls is an important part of regulatory compliance.
For consumers, the immediate dispute is primarily an administrative and regulatory matter. Reports on the case have also made clear that Cipla has stated that the FDA action did not allege concerns about the safety, quality or efficacy of its products.
The distinction between regulatory compliance issues and a finding that a medicine is unsafe is therefore important when reporting the matter.
The pharmaceutical industry is closely regulated because medicines directly affect public health. Regulatory authorities are expected to respond firmly when companies violate applicable rules. However, enforcement actions must also follow established legal procedures.
The Bombay High Court’s observations in the Cipla case reinforce that principle.
The latest development means the licence cancellation order has been withdrawn, but the regulatory dispute itself has not necessarily ended. A fresh notice and further proceedings are expected.
The FDA will now have to reconsider the allegations through the prescribed process and determine whether further action is justified.
Cipla, meanwhile, will have an opportunity to formally respond to the allegations during the fresh proceedings.
The case is likely to remain significant for both the pharmaceutical industry and regulatory authorities because it demonstrates how enforcement decisions can be challenged when companies believe proper procedural safeguards have not been followed.
The final outcome will depend on the fresh proceedings and the reasoned decision eventually issued by the Maharashtra FDA.
For now, the key development is that the FDA has withdrawn its earlier cancellation order following the Bombay High Court’s criticism of the procedure. The regulator has agreed to restart the process by issuing a fresh show cause notice.
The case therefore moves from an immediate licence cancellation to a renewed regulatory examination, with both sides expected to present their positions before a fresh decision is made.